Top-Rated StocksTop-RatedNASDAQ:RLAY Relay Therapeutics (RLAY) Stock Forecast, Price & News $8.41 +0.17 (+2.06%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$8.16▼$8.5550-Day Range$8.24▼$12.6052-Week Range$7.82▼$24.17Volume882,617 shsAverage Volume1.12 million shsMarket Capitalization$1.03 billionP/E RatioN/ADividend YieldN/APrice Target$26.06 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Relay Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.90 Rating ScoreUpside/Downside209.8% Upside$26.06 Price TargetShort InterestBearish23.71% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.16Based on 3 Articles This WeekInsider TradingSelling Shares$43,825 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.28) to ($3.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.56 out of 5 starsMedical Sector895th out of 972 stocksBiological Products, Except Diagnostic Industry145th out of 155 stocks 3.5 Analyst's Opinion Consensus RatingRelay Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $26.06, Relay Therapeutics has a forecasted upside of 209.8% from its current price of $8.41.Amount of Analyst CoverageRelay Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted23.71% of the float of Relay Therapeutics has been sold short.Short Interest Ratio / Days to CoverRelay Therapeutics has a short interest ratio ("days to cover") of 21, which indicates bearish sentiment.Change versus previous monthShort interest in Relay Therapeutics has recently increased by 0.96%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRelay Therapeutics does not currently pay a dividend.Dividend GrowthRelay Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RLAY. Previous Next 2.9 News and Social Media Coverage News SentimentRelay Therapeutics has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Relay Therapeutics this week, compared to 2 articles on an average week.Search Interest3 people have searched for RLAY on MarketBeat in the last 30 days. MarketBeat Follows5 people have added Relay Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Relay Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $43,825.00 in company stock.Percentage Held by InsidersOnly 3.54% of the stock of Relay Therapeutics is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Relay Therapeutics are expected to decrease in the coming year, from ($3.28) to ($3.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Relay Therapeutics is -2.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Relay Therapeutics is -2.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRelay Therapeutics has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Relay Therapeutics (NASDAQ:RLAY) StockRelay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and GDC-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More RLAY Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RLAY Stock News HeadlinesSeptember 24, 2023 | americanbankingnews.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Rating of "Moderate Buy" by BrokeragesSeptember 18, 2023 | finance.yahoo.comRelay Therapeutics to Present Clinical Data on RLY-4008 in Advanced FGFR2-Altered Solid Tumors at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsOctober 1, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...August 9, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Ansell (OtherANSLF) and Relay Therapeutics (RLAY)August 9, 2023 | msn.comOppenheimer Reiterates Relay Therapeutics (RLAY) Outperform RecommendationAugust 8, 2023 | finance.yahoo.comRelay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue EstimatesAugust 8, 2023 | finance.yahoo.comRelay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate HighlightsAugust 1, 2023 | finance.yahoo.comRelay Therapeutics to Announce Second Quarter 2023 Financial Results and Corporate Highlights on August 8, 2023October 1, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...July 28, 2023 | seekingalpha.comRelay Therapeutics: Market May Be Prematurely Dismissing RLY-2608July 3, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Relay Therapeutics (RLAY), Bright Health Group (BHG) and Bausch + Lomb Corporation (BLCO)June 10, 2023 | msn.comHC Wainwright & Co. Maintains Relay Therapeutics (RLAY) Buy RecommendationJune 9, 2023 | msn.com11 Analysts Have This to Say About Relay TherapeuticsJune 5, 2023 | markets.businessinsider.comBarclays Sticks to Its Hold Rating for Relay Therapeutics (RLAY)May 18, 2023 | finance.yahoo.comIs Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Deliver On Growth Plans?May 12, 2023 | seekingalpha.comRelay Therapeutics May 2023 Corporate PresentationMay 9, 2023 | seekingalpha.comRelay Therapeutics: Selloff On Poor Breast Cancer Data May Have Been OverblownMay 9, 2023 | markets.businessinsider.comBerenberg Bank Sticks to Their Buy Rating for Relay Therapeutics (RLAY)May 5, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Lantheus (LNTH) and Relay Therapeutics (RLAY)May 4, 2023 | msn.comRelay Therapeutics: Q1 Earnings InsightsMay 4, 2023 | finance.yahoo.comRelay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Misses Revenue EstimatesMay 3, 2023 | msn.comEarnings Outlook For Relay TherapeuticsApril 26, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Relay Therapeutics (RLAY) and CureVac (CVAC)April 20, 2023 | msn.comStifel Maintains Relay Therapeutics (RLAY) Buy RecommendationApril 20, 2023 | msn.comJefferies Upgrades Relay Therapeutics (RLAY)April 20, 2023 | markets.businessinsider.comWhat 11 Analyst Ratings Have To Say About Relay TherapeuticsApril 20, 2023 | finance.yahoo.com4 big analyst picks: BofA ups composite decking stocks Azek, Trex | Pro RecapSee More Headlines Receive RLAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Relay Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RLAY Company Calendar Last Earnings8/08/2023Today10/01/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RLAY CUSIPN/A CIK1812364 Webwww.relaytx.com Phone617-370-8837FaxN/AEmployees345Year FoundedN/APrice Target and Rating Average Stock Price Forecast$26.06 High Stock Price Forecast$34.00 Low Stock Price Forecast$12.50 Forecasted Upside/Downside+209.8%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-290,510,000.00 Net Margins-36,562.53% Pretax Margin-36,562.53% Return on Equity-37.81% Return on Assets-32.28% Debt Debt-to-Equity RatioN/A Current Ratio12.35 Quick Ratio12.36 Sales & Book Value Annual Sales$1.38 million Price / Sales744.29 Cash FlowN/A Price / Cash FlowN/A Book Value$7.86 per share Price / Book1.07Miscellaneous Outstanding Shares122,130,000Free Float117,810,000Market Cap$1.03 billion OptionableNot Optionable Beta1.38 10 Best Stocks to Own in 2023Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Alexis A. Borisy A.M. (Age 51)Co-Founder & Independent Chairman Comp: $85kDr. Sanjiv K. Patel M.A. (Age 49)M.B.A., M.D., MBBS, CEO, Pres & Director Comp: $1.03MDr. Mark Murcko Ph.D. (Age 63)Co-Founder & Director Comp: $50kMr. Thomas Catinazzo (Age 46)Chief Financial Officer Comp: $599.83kMr. Brian R. Adams J.D. (Age 49)Chief Legal Officer & Sec. Comp: $598.53kDr. Donald A. Bergstrom M.D. (Age 51)Ph.D., Pres of R&D Comp: $711.25kMr. Peter RahmerChief Corp. Devel. OfficerDr. Deborah Palestrant Ph.D.VP of Corp. Devel. & StrategyMr. Jim Watters Ph.D.Chief Scientific Officer of Late ResearchDr. Beni B. Wolf M.D.Ph.D., Chief Medical Officer & Head of Precision MedicineMore ExecutivesKey CompetitorsProKidneyNASDAQ:PROKPrime MedicineNYSE:PRMEApogee TherapeuticsNASDAQ:APGEReplimune GroupNASDAQ:REPLIovance BiotherapeuticsNASDAQ:IOVAView All CompetitorsInsiders & InstitutionsDonald A BergstromSold 648 sharesTotal: $5,430.24 ($8.38/share)Thomas CatinazzoSold 294 sharesTotal: $2,463.72 ($8.38/share)Virginia Retirement Systems ET ALBought 12,200 shares on 8/22/2023Ownership: 0.010%California State Teachers Retirement SystemSold 1,257 shares on 8/21/2023Ownership: 0.081%Nuveen Asset Management LLCBought 9,145 shares on 8/16/2023Ownership: 0.213%View All Insider TransactionsView All Institutional Transactions RLAY Stock - Frequently Asked Questions Should I buy or sell Relay Therapeutics stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Relay Therapeutics in the last twelve months. There are currently 2 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RLAY shares. View RLAY analyst ratings or view top-rated stocks. What is Relay Therapeutics' stock price forecast for 2023? 10 brokers have issued 1 year price objectives for Relay Therapeutics' shares. Their RLAY share price forecasts range from $12.50 to $34.00. On average, they predict the company's stock price to reach $26.06 in the next year. This suggests a possible upside of 209.8% from the stock's current price. View analysts price targets for RLAY or view top-rated stocks among Wall Street analysts. How have RLAY shares performed in 2023? Relay Therapeutics' stock was trading at $14.94 at the beginning of 2023. Since then, RLAY shares have decreased by 43.7% and is now trading at $8.41. View the best growth stocks for 2023 here. When is Relay Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our RLAY earnings forecast. How were Relay Therapeutics' earnings last quarter? Relay Therapeutics, Inc. (NASDAQ:RLAY) released its earnings results on Tuesday, August, 8th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.78) by $0.03. The business earned $0.12 million during the quarter, compared to analysts' expectations of $0.81 million. Relay Therapeutics had a negative net margin of 36,562.53% and a negative trailing twelve-month return on equity of 37.81%. Relay Therapeutics's revenue for the quarter was down 67.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.71) earnings per share. What ETFs hold Relay Therapeutics' stock? ETFs with the largest weight of Relay Therapeutics (NASDAQ:RLAY) stock in their portfolio include TrueShares Technology, AI & Deep Learning ETF (LRNZ), Range Cancer Therapeutics ETF (CNCR) and SPDR S&P Biotech ETF (XBI).Virtus LifeSci Biotech Clinical Trials ETF (BBC). What other stocks do shareholders of Relay Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Relay Therapeutics investors own include Beyond Meat (BYND), CureVac (CVAC), QuidelOrtho (QDEL), Teladoc Health (TDOC), Tesla (TSLA), Datadog (DDOG), DraftKings (DKNG), eHealth (EHTH), GoHealth (GOCO) and Intel (INTC). When did Relay Therapeutics IPO? (RLAY) raised $250 million in an IPO on Thursday, July 16th 2020. The company issued 14,700,000 shares at $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs, Cowen and Guggenheim Securities acted as the underwriters for the IPO. What is Relay Therapeutics' stock symbol? Relay Therapeutics trades on the NASDAQ under the ticker symbol "RLAY." How do I buy shares of Relay Therapeutics? Shares of RLAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Relay Therapeutics' stock price today? One share of RLAY stock can currently be purchased for approximately $8.41. How much money does Relay Therapeutics make? Relay Therapeutics (NASDAQ:RLAY) has a market capitalization of $1.03 billion and generates $1.38 million in revenue each year. The company earns $-290,510,000.00 in net income (profit) each year or ($2.91) on an earnings per share basis. How many employees does Relay Therapeutics have? The company employs 345 workers across the globe. How can I contact Relay Therapeutics? Relay Therapeutics' mailing address is 399 BINNEY STREET 2ND FLOOR, CAMBRIDGE MA, 02139. The official website for the company is www.relaytx.com. The company can be reached via phone at 617-370-8837 or via email at prahmer@relaytx.com. This page (NASDAQ:RLAY) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.